AR024570A1 - Una composicion farmaceutica para uso oral, un metodo para su manufacturacion y un metodo para su estabilizacion. - Google Patents
Una composicion farmaceutica para uso oral, un metodo para su manufacturacion y un metodo para su estabilizacion.Info
- Publication number
- AR024570A1 AR024570A1 ARP000102986A ARP000102986A AR024570A1 AR 024570 A1 AR024570 A1 AR 024570A1 AR P000102986 A ARP000102986 A AR P000102986A AR P000102986 A ARP000102986 A AR P000102986A AR 024570 A1 AR024570 A1 AR 024570A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- carboxyamidino
- oxazolidinyl
- oxo
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- -1 1-ethyl methyl Chemical group 0.000 abstract 6
- 239000004480 active ingredient Substances 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000003860 storage Methods 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 abstract 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 125000000160 oxazolidinyl group Chemical group 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composicion farmacéutica estabilizada para uso oral que contiene 1-etil metiléster del acetato de 4-[[3-[p-(carboxiamidino)fenil]-2-oxo-5-oxazolidinil]metil]-1-piperazina,o una de sus sales aceptables desde el punto de vista farmacéutico y unaba se aceitosa que se elige preferentemente entre uno o máscompuestos pertenecientes al grupo formado por los ácidos grasos de alto peso molecular, los ésteres de ácido graso y alcohol, los alcoholes superiores, losfosfolípidos,el esterol o susésteres y los hidrocarburos.Un método para manufacturar una composicion farmacéutica estabilizada para uso oral, por medio delcual se combina el 1-etil metiléster del acetato de4-[[3-[p-(carboxiamidino)fenil]-2-oxo-5-oxazolidinil]metil]-1-piperazina, o una de sus sales aceptablesdesde el punto de vista farmacéutico, con una base aceitosa. Un método para estabilizar una composicion farmacéutica por combinacion del 1-etilmetiléster delacetato de 4-[[3-[p-(carboxiamidino)fenil]-2-oxo-5-oxazolidinil]metil ]-1-piperazina, o de una de sus sales aceptables desde el punto de vista fisiologico, conuna base aceitosa. Esta composicion farmacéutica permite evitar o prevenirla disminucion de seguridad ocasionada por la incompativilidad aun durante elalmacenam iento o la preservacion,y también evitar el decrecimiento de la actividad farmacologica del ingrediente activo durante el procedimiento de manufacturacion.Porconsiguiente, con dicha preparacion farmacéutica se puede mantener una actividad suficient emente controlada del ingrediente activo durante un períodousual de almacenamiento y se puede esperar un efecto terapéutico más seguro. Por otra parte, elingrediente activo mencionado más arriba tiene una accionantagnoista del receptor GPIIb/IIIa, p or lo que puede ser empleado sin riesgos para el tratamiento de la trombosis, la apoplejía, el infarto de miocardio, laangina de pecho, las enfermedadesosteolíticas (en particular, la osteoporosis), la estenosis recurrente después de la angiogénesis , las isquemias, lasinflamaciones, la arteriosclerosis y las deficiencias renales agudas, siendo particularmente util como inhibidor de la agregacionplaquetaria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17223799 | 1999-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024570A1 true AR024570A1 (es) | 2002-10-16 |
Family
ID=15938170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102986A AR024570A1 (es) | 1999-06-18 | 2000-06-16 | Una composicion farmaceutica para uso oral, un metodo para su manufacturacion y un metodo para su estabilizacion. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6525058B1 (es) |
| EP (1) | EP1188440A4 (es) |
| KR (1) | KR20020038591A (es) |
| CN (1) | CN1172671C (es) |
| AR (1) | AR024570A1 (es) |
| AU (1) | AU5249500A (es) |
| CA (1) | CA2376155A1 (es) |
| WO (1) | WO2000078318A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| CN102186474A (zh) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874795A (en) * | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
| CA2038744C (en) * | 1990-03-23 | 2002-01-08 | Yoshitomi Pharmaceutical Industries Ltd. | Pharmaceutical composition containing slightly water-soluble drug |
| DE19516483A1 (de) * | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US6013665A (en) * | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| US6579880B2 (en) * | 2000-06-06 | 2003-06-17 | Ortho-Mcneil Pharmaceutical, Inc. | Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8 |
-
2000
- 2000-06-16 KR KR1020017016208A patent/KR20020038591A/ko not_active Application Discontinuation
- 2000-06-16 US US10/009,797 patent/US6525058B1/en not_active Expired - Fee Related
- 2000-06-16 EP EP00937275A patent/EP1188440A4/en not_active Withdrawn
- 2000-06-16 WO PCT/JP2000/003940 patent/WO2000078318A1/ja not_active Application Discontinuation
- 2000-06-16 CN CNB008083290A patent/CN1172671C/zh not_active Expired - Fee Related
- 2000-06-16 AR ARP000102986A patent/AR024570A1/es unknown
- 2000-06-16 AU AU52495/00A patent/AU5249500A/en not_active Abandoned
- 2000-06-16 CA CA002376155A patent/CA2376155A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU5249500A (en) | 2001-01-09 |
| EP1188440A4 (en) | 2004-04-14 |
| CA2376155A1 (en) | 2000-12-28 |
| KR20020038591A (ko) | 2002-05-23 |
| CN1172671C (zh) | 2004-10-27 |
| WO2000078318A1 (fr) | 2000-12-28 |
| EP1188440A1 (en) | 2002-03-20 |
| CN1353610A (zh) | 2002-06-12 |
| US6525058B1 (en) | 2003-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| ES2661487T3 (es) | Preconcentrado lipídico de liberación sostenida de sustancia farmacológicamente activa y composición farmacéutica que comprende el mismo | |
| CO6220926A2 (es) | Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid) | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| RU2012137785A (ru) | Лечение респираторных заболеваний | |
| ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
| ES2195798T1 (es) | Formulacion para mujeres menopausicas. | |
| EP1534298A2 (en) | Novel anticholesterol compositions and method for using same | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| DE69927963D1 (de) | Gelierbare pharmazeutische zusammensetzungen | |
| US20110275717A1 (en) | Pharmaceutical formulation comprising diclofenac | |
| RU2002122744A (ru) | Новая самоэмульгирующаяся система доставки лекарств | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| RU2012130421A (ru) | Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ | |
| ES2576740T3 (es) | Composiciones farmacéuticas tópicas que incluyen REL-N-[6-[(2R,6S)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida | |
| CO4900080A1 (es) | Microesferas farmaceuticas de acido valproico para administracion oral | |
| PE20040158A1 (es) | Sales de nateglinida | |
| WO2009008487A1 (ja) | 被覆製剤 | |
| UY26303A1 (es) | Composiciones farmacéuticas para administración oral y tópica | |
| JP2008522972A5 (es) | ||
| RU2012150409A (ru) | Препарат ацеклофенака с медленным высвобождением, обеспечивающий оптимальное фармакологическое и клиническое действие при приеме один раз в день | |
| US5665384A (en) | Oily capsules of ketoprofen | |
| AR024570A1 (es) | Una composicion farmaceutica para uso oral, un metodo para su manufacturacion y un metodo para su estabilizacion. |